Physician profile
Kassi Avent
NPI 1861840043
$1,936.00
in general payments reported to CMS, 2019-2025
18 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $33.84 · 2022: $17.43 · 2023: $401 · 2024: $837 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712 · Consulting Fee: $30.00 · Education: $21.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.17 |
| Consulting Fee | $30.00 |
| Education | $21.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $357.11 | 2023-2024 | Descovy, Epclusa |
| Exact Sciences Corporation | $322.47 | 2023-2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $288.57 | 2023-2025 | Apretude, Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $236.32 | 2020-2025 | Delstrigo, Pifeltro, Dificid |
| Sanofi-Aventis U.S. LLC | $145.08 | 2025 | |
| Braeburn INC. | $125.00 | 2025 | Brixadi |
| Regeneron Healthcare Solutions, INC. | $120.82 | 2019 | |
| Novo Nordisk INC | $68.34 | 2023-2025 | Ozempic, Rybelsus |
| Theratechnologies INC. | $60.20 | 2023-2025 | Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $48.25 | 2023-2024 | Mytesi |
| Abbvie INC. | $30.58 | 2023 | Vraylar |
| Medicines360 | $30.00 | 2023 | Liletta |
| Bayer Healthcare Pharmaceuticals INC. | $19.02 | 2020 | |
| Sanofi Pasteur INC. | $18.23 | 2023 | |
| Indivior INC. | $18.17 | 2025 | Sublocade |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $17.43 | 2022 | |
| Antares Pharma, INC. | $16.38 | 2025 | Xyosted |
| Lundbeck LLC | $14.03 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kassi Avent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.